Eris Lifesciences Limited Stock Bombay S.E.

Equities

ERIS

INE406M01024

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:50 2024-04-19 am EDT 5-day change 1st Jan Change
873.7 INR +0.40% Intraday chart for Eris Lifesciences Limited +3.52% -4.05%
Sales 2024 * 19.71B 236M Sales 2025 * 26.49B 317M Capitalization 118B 1.42B
Net income 2024 * 4.1B 49.06M Net income 2025 * 4.38B 52.44M EV / Sales 2024 * 6.54 x
Net Debt 2024 * 10.44B 125M Net Debt 2025 * 11.22B 134M EV / Sales 2025 * 4.89 x
P/E ratio 2024 *
29 x
P/E ratio 2025 *
26.7 x
Employees 3,548
Yield 2024 *
0.78%
Yield 2025 *
0.79%
Free-Float 24.65%
More Fundamentals * Assessed data
Dynamic Chart
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business MT
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion MT
Transcript : Eris Lifesciences Limited - Shareholder/Analyst Call
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million RE
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion. CI
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals MT
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited. CI
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026 CI
Transcript : Eris Lifesciences Limited, Q3 2024 Earnings Call, Feb 13, 2024
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion. CI
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns RE
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics CI
Indian shares set to open higher tracking Asian peers RE
More news

Latest transcript on Eris Lifesciences Limited

1 day+0.98%
1 week+3.88%
Current month+4.47%
1 month+3.61%
3 months-1.39%
6 months+1.31%
Current year-3.49%
More quotes
1 week
825.00
Extreme 825
885.00
1 month
825.00
Extreme 825
885.00
Current year
810.10
Extreme 810.1
960.90
1 year
602.05
Extreme 602.05
971.00
3 years
550.90
Extreme 550.9
971.00
5 years
341.05
Extreme 341.05
971.00
10 years
341.05
Extreme 341.05
971.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 07-01-26
President - 10-04-30
Director of Finance/CFO 44 12-12-31
Members of the board TitleAgeSince
Director/Board Member 53 21-01-04
Director/Board Member 44 18-04-29
Chief Executive Officer 50 07-01-26
More insiders
Date Price Change Volume
24-04-19 873.7 +0.40% 4 216
24-04-18 870.2 +0.31% 9,652
24-04-16 867.6 +1.56% 7,148
24-04-15 854.3 +0.98% 4,487
24-04-12 846 +0.24% 1,459

Delayed Quote Bombay S.E., April 19, 2024 at 03:45 am EDT

More quotes
Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals, and nutrients (VMN). The Company's brands include Advog 0.2, Atorsave Gold 10, Baga NT 100, Calshine 60K Tablet, Carpela, Cilentra Plus 5, Cognix, D1000cal, Enoxsave 60, Glimisave M 4 forte, Levroxa 1000, Mac Rabonik Plus, Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited, and Eris Healthcare Private Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
870.3 INR
Average target price
1,081 INR
Spread / Average Target
+24.17%
Consensus

Quarterly revenue - Rate of surprise